Sep 25 |
Amgen Stock Falls on Disappointing Drug Data
|
Sep 25 |
Amgen Biosimilar And EYLEA Patent Dispute: What It Means For Regeneron Investors
|
Sep 24 |
US Equity Indexes Rise as Sliding Consumer Confidence Undermines Bowman's Call for Policy Caution
|
Sep 24 |
Regeneron Stock Down on Court Ruling for Amgen's Biosimilar of Eylea
|
Sep 24 |
Regeneron slump continues as analysts turn more cautious
|
Sep 24 |
HRMY vs. REGN: Which Stock Should Value Investors Buy Now?
|
Sep 24 |
Regeneron downgraded at Leerink after Amgen’s court win; Truist defends
|
Sep 23 |
Regeneron Stock Slides After Court Rejects Injunction Against Eye Drug Biosimilar, Truist Says
|
Sep 23 |
Tesla Leads S&P 500 Index, While Biotech Giant Tumbles On Court Ruling
|
Sep 23 |
Regeneron Dives As Amgen Tees Up Its Rival To Moneymaking Machine Eylea
|